Abstract 463P
Background
Delirium represents global brain dysfunction caused by an underlying medical condition. In cancer, it is associated with worse outcome. Antipsychotic medications have been widely used, however evidence in cancer populations is still limited with concern of potential adverse effects.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used in this systematic review were antipsychotic agents, delirium, and neoplasm. Publications were limited to English manuscripts published in the last 15 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review included 11 studies with a total of 1,896 patients aged 23 to 99. The cancer types varied and included lungs, gastrointestinal, hepatobiliary, urological, breast, head and neck, pancreas, lymphoma, sarcoma, and skin cancers. Some studies involved patients with brain metastasis and central nervous system lesions. These studies covered different cancer stages, including advanced, terminal, and localized. The antipsychotic medications examined in this review were haloperidol, quetiapine, chlorpromazine/levomepromazine, olanzapine, risperidone, trazodone, aripiprazole, and perospirone. Both typical and atypical antipsychotics were found to be similarly effective in managing delirium, but typical antipsychotics were associated with a higher prevalence of extrapyramidal symptoms. Higher antipsychotic doses were linked to increased mortality in cancer patients with delirium. Delirium outcomes were assessed using scales such as the Memorial Delirium Assessment Scale (MDAS), Richmond Agitation-Sedation Scale Palliative version (RASS-PAL), and others. Adverse events included hypotension, hypokinesia, sedation, extrapyramidal symptoms, falls, aspiration pneumonia, and urinary retention. Notably, no deaths were reported as a result of antipsychotic therapy.
Conclusions
Antipsychotic interventions to manage delirium in cancer patients consistently showed positive effects in addressing immediate distress and become a meaningful component of end-of-life support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract